A

Andreas Jung

Ludwig-Maximilians-Universität München

ORCID: 0000-0001-5270-9108

400 papers and 21.4k citations.

PubIndex Score98Top 2%How it's scored

400Publications

21.4kTotal Citations

First publication: 1926First senior author: 1988

Top publicationsby citations

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al.|The Lancet Oncology|2014

Cited by 1.7k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Volker Heinemann, Frank Kullmann et al.|The Lancet Oncology|2016

Cited by 417

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Anke Reinacher‐Schick, Ingrid Ricard et al.|Annals of Oncology|2016

Cited by 344

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR

Volker Heinemann, Andreas Jung, Sebastian Stintzing et al.|Cancer Treatment Reviews|2008

Cited by 205

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sebastian Stintzing, Volker Heinemann, Pratyaksha Wirapati et al.|Annals of Oncology|2019

Cited by 194

Indexing the rest of 400 publications…